Structural and functional properties of region II-plus of the malaria circumsporozoite protein. 1994

P Sinnis, and P Clavijo, and D Fenyö, and B T Chait, and C Cerami, and V Nussenzweig
Michael Heidelberger Division of Immunology, Department of Pathology, New York University Medical Center, New York 10016.

During feeding, infected mosquitos inject malaria sporozoites into the host circulation. Within minutes, the parasites are found in the liver where they initiate the first stage of malaria infection. All species of malaria sporozoites are uniformly covered by the circumsporozoite protein (CS), which contains a conserved COOH-terminal sequence called region II-plus. We have previously shown that region II-plus is the parasite's hepatocyte-binding ligand and that this ligand binds to heparan sulfate proteoglycans (HSPGs) on the hepatocyte membrane. Using a series of substituted region II-plus peptides, we show here that the downstream basic amino acids as well as the interdispersed hydrophobic residues are required for binding of CS to hepatocyte HSPGs. We also show that this positively charged stretch of amino acids must be aggregated in order to bind to the receptor. On the basis of this information, we have synthesized a multiple antigen peptide that mimics the hepatocyte-binding ligand. This construct inhibits both CS binding to HepG2 cells in vitro as well as CS clearance in mice.

UI MeSH Term Description Entries
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D008970 Molecular Weight The sum of the weight of all the atoms in a molecule. Molecular Weights,Weight, Molecular,Weights, Molecular
D011509 Proteoglycans Glycoproteins which have a very high polysaccharide content. Proteoglycan,Proteoglycan Type H
D005260 Female Females
D006497 Heparitin Sulfate A heteropolysaccharide that is similar in structure to HEPARIN. It accumulates in individuals with MUCOPOLYSACCHARIDOSIS. Heparan Sulfate,Sulfate, Heparan,Sulfate, Heparitin
D000595 Amino Acid Sequence The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION. Protein Structure, Primary,Amino Acid Sequences,Sequence, Amino Acid,Sequences, Amino Acid,Primary Protein Structure,Primary Protein Structures,Protein Structures, Primary,Structure, Primary Protein,Structures, Primary Protein
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

P Sinnis, and P Clavijo, and D Fenyö, and B T Chait, and C Cerami, and V Nussenzweig
January 2021, NPJ vaccines,
P Sinnis, and P Clavijo, and D Fenyö, and B T Chait, and C Cerami, and V Nussenzweig
February 1997, Experimental parasitology,
P Sinnis, and P Clavijo, and D Fenyö, and B T Chait, and C Cerami, and V Nussenzweig
September 1990, Science (New York, N.Y.),
P Sinnis, and P Clavijo, and D Fenyö, and B T Chait, and C Cerami, and V Nussenzweig
December 1988, Molecular biology & medicine,
P Sinnis, and P Clavijo, and D Fenyö, and B T Chait, and C Cerami, and V Nussenzweig
January 2021, Frontiers in immunology,
P Sinnis, and P Clavijo, and D Fenyö, and B T Chait, and C Cerami, and V Nussenzweig
June 1997, The New England journal of medicine,
P Sinnis, and P Clavijo, and D Fenyö, and B T Chait, and C Cerami, and V Nussenzweig
June 1997, The New England journal of medicine,
P Sinnis, and P Clavijo, and D Fenyö, and B T Chait, and C Cerami, and V Nussenzweig
June 1997, The New England journal of medicine,
P Sinnis, and P Clavijo, and D Fenyö, and B T Chait, and C Cerami, and V Nussenzweig
February 2021, Expert review of vaccines,
P Sinnis, and P Clavijo, and D Fenyö, and B T Chait, and C Cerami, and V Nussenzweig
August 1989, Blood,
Copied contents to your clipboard!